Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The Growing Cases of Liver Cancer
4.1.1.2. Market Developments
4.1.2. Restraints
4.1.2.1. High Cost of diagnosis and treatment
4.1.2.2. Treatment Side Effects
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Hepatocellular Carcinoma
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Cholangio Carcinoma
7.4. Hepatoblastoma
7.5. Other
8. By Therapy Type
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
8.1.2. Market Attractiveness Index, By Therapy Type
8.2. Targeted Therapy*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Radiation Therapy
8.4. Immunotherapy
8.5. Chemotherapy
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals And Clinics
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. ASCs
9.4. Cancer Rehabilitation Centers
10. By Country
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Country
10.1.2. Market Attractiveness Index, By Country
10.2. Germany
10.2.1. Introduction
10.2.2. Key Country-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3. U.K.
10.3.1. Introduction
10.3.2. Key Country-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4. France
10.4.1. Introduction
10.4.2. Key Country-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5. Italy
10.5.1. Introduction
10.5.2. Key Country-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.6. Spain
10.6.1. Introduction
10.6.2. Key Country-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.7. Rest of Europe
10.7.1. Introduction
10.7.2. Key Country-Specific Dynamics
10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
12. Company Profiles
12.1. Amgen Inc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. AstraZeneca PLC
12.3. Bayer AG
12.4. Celgene Corporation
12.5. Eli Lilly
12.6. Bristol-Myers Squibb Company
12.7. Gilead Sciences, Inc.
12.8. Takeda Pharmaceutical Company Limited
12.9. Daiichi Sankyo Company, Limited
12.10. UCB SA
LIST NOT EXHAUSTIVE
13. DataM
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us